
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly reported a robust second-quarter performance for 2025, surpassing expectations on both revenue and earnings while also raising its full-year guidance, indicating strong operational momentum. Notably, Mounjaro experienced a significant 60% quarter-over-quarter sales growth internationally, propelled by successful launches in key markets like Brazil, Mexico, and India. Additionally, the anticipated introduction of orforglipron presents an attractive new option in the GLP-1 market, suggesting strong future growth potential for Eli Lilly's portfolio in the cardiometabolic segment.
Bears say
Eli Lilly faces significant downside risks that may negatively impact its stock performance, including potential pricing and rebate pressures, disappointing prescription trajectories for its key drug, tirzepatide (Mounjaro), and the possibility that it will fail to demonstrate cardiac benefits in certain patient populations. Additionally, the recent adverse trend in prescriptions for Zepbound is expected to hinder revenue growth in the upcoming quarter, further stressing the company's sales outlook. The competitive landscape, particularly from orforglipron, poses a substantial threat, leading to adjustments in peak sales forecasts and increasing uncertainty around future revenue generation.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares